Therapeutic Solutions International, Inc.
TSOI · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -52.1% | 41.7% | 132.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 62.9% | 61.6% | 70.9% | 79.6% |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $1 | $2 | $2 | $1 |
| SG&A Expenses | $1 | $2 | $2 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $3 | $2 | $2 |
| Operating Income | -$2 | -$3 | -$2 | -$2 |
| % Margin | -2,006.7% | -1,586% | -1,578.8% | -2,950.8% |
| Other Income/Exp. Net | -$0 | -$1 | -$1 | -$0 |
| Pre-Tax Income | -$2 | -$4 | -$3 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$4 | -$3 | -$2 |
| % Margin | -2,191.9% | -1,844.6% | -2,029% | -3,509.7% |
| EPS | -0.001 | -0.002 | -0.001 | -0.001 |
| % Growth | 53.3% | -15.4% | -8.3% | – |
| EPS Diluted | -0.001 | -0.002 | -0.001 | -0.001 |
| Weighted Avg Shares Out | 3,169 | 2,528 | 2,263 | 1,912 |
| Weighted Avg Shares Out Dil | 3,169 | 2,528 | 2,263 | 1,912 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $1 | $1 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$3 | -$2 | -$2 |
| % Margin | -1,502.5% | -1,444% | -1,596.9% | -3,016% |